|Bid||0.5708 x 1300|
|Ask||0.5734 x 3000|
|Day's range||0.5529 - 0.5835|
|52-week range||0.4340 - 1.6200|
|Beta (5Y monthly)||3.02|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Aurora Cannabis (NASDAQ: ACB) might seem like another humdrum marijuana stock, but there are actually a few nuances and recent developments that mean that there's a bit more than meets the eye. This will equip you to make the best investment decision regarding Aurora Cannabis. Aurora's home market is in Canada, where it sells medicinal marijuana.
Stocks in the cannabis sector have been bid up in recent weeks thanks to some political news surrounding marijuana's legal status in the United States. Aurora Cannabis (NASDAQ: ACB) has been one of them with a 50% gain over the last month. Today, however, Aurora stock is getting hit hard.
All of the biggest public marijuana companies massively underperformed the market over the last 12 months, with nearly all of them losing a lot of their value, and there may not be relief in sight. Canopy Growth (NASDAQ: CGC) is a Canadian cultivator that looks cheap and appears to be exposed to a lot of upside from cannabis legalization in the U.S., but it's a trap. As you can see, Canopy's price-to-sales (P/S) multiple of 1.5 is significantly lower than its peers like Tilray Brands, Curaleaf and Green Thumb Industries.